Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Cloning and functional analysis of <i>MdCRCT1</i> in the regulation of drought tolerance in apple.

Physiology and molecular biology of plants : an international journal of functional plant biology·2026
Same author

A Targeted Analysis of The Donor Human Milk Metabolome & Implications for Preterm Infant Nutrition.

The Journal of nutrition·2026
Same author

A Gradient-Guided Spatio-Temporal Graph Convolutional Network for Population-Level Major Depressive Disorder Classification.

IEEE journal of biomedical and health informatics·2026
Same author

Dual-engine amplification: Integrating catalytic hairpin assembly with CRISPR-Cas12a for ultrasensitive point-of-care testing of Chikungunya virus RNA.

Talanta·2026
Same author

The Current Application Prospects of Nanomedicine in Renal Ischemia-Reperfusion Injury.

International journal of nanomedicine·2026
Same author

Advancements in Nanomaterial-Based Biosensors for Neuropsychiatric and Neurodegenerative Diagnostics: From Biomarker Discovery to Clinical Translation.

Biosensors·2026

相关实验视频

Updated: Jul 1, 2026

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

12.3K

纳米输送系统用于动脉样硬化.

Zhuoyi Rong1, Xuan He1, Tianjian Fan1

  • 1Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China.

Journal of functional biomaterials
|January 24, 2025
PubMed
概括

纳米粒子为动脉样硬化药物输送提供了更好的安全性和有效性,解决了当前治疗方法的局限性. 这篇评论探讨了纳米粒子的进步,挑战和心血管疾病治疗的未来方向.

科学领域:

  • 心血管科学 心血管科学
  • 生物医学工程 生物医学工程
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 动脉样硬化是心血管疾病的主要原因,由炎症和脂质驱动.
  • 目前用于动脉样硬化治疗的药物治疗有局限性,包括稳定性差和副作用.
  • 纳米材料正在成为针对药物输送的有希望的工具.

研究的目的:

  • 审查纳米颗粒在提高动脉样硬化药物安全性和疗效方面的作用.
  • 讨论基于纳米粒子的药物输送系统的开发和优化.
  • 探索纳米粒子应用在动脉样硬化中的当前挑战和未来机遇.

主要方法:

  • 对用于动脉样硬化治疗的基于纳米粒子的药物输送系统的文献综述.
  • 对专注于脂质体和聚合物纳米粒子的研究进行分析.
  • 讨论纳米粒子优化策略和临床翻译.

主要成果:

  • 纳米颗粒显示出提高药物稳定性和减少动脉样硬化治疗中的副作用的潜力.
  • 各种纳米粒子配方显示出有希望的治疗剂的向输送.
  • 目前正在进行的研究重点是优化纳米粒子设计和制造.
关键词:
动脉样硬化 动脉样硬化动脉样硬化的斑块纳米材料是一种纳米材料.纳米颗粒是一种纳米粒子.他们是天文学家.

更多相关视频

Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis
08:13

Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis

Published on: March 22, 2016

10.5K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

8.9K

相关实验视频

Last Updated: Jul 1, 2026

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

12.3K
Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis
08:13

Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis

Published on: March 22, 2016

10.5K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

8.9K

结论:

  • 基于纳米粒子的药物输送代表了动脉样硬化治疗的重大进步.
  • 需要进一步的研究和开发,以克服临床应用中的挑战.
  • 纳米材料对未来的心血管疾病管理具有相当大的前景.